Article Text

AB0578 Anti-tnfa therapy in psoriatic arthritis: different rate of remission in polyarticular and oligoarticular subsets
  1. F. Iannone1,
  2. S. Lopriore1,
  3. R. Bucci2,
  4. C. Scioscia1,
  5. M. G. Anelli1,
  6. M. Covelli1,
  7. G. Lapadula1
  1. 1Rheumatology Unit - University Of Bari, Bari
  2. 2Rheumatology Unit, Ospedali Riuniti di Foggia, Foggia, Italy


Objectives To compare the efficacy of adalimumab, etanercept, and infliximab therapy in psoriatic arthritis (PsA) patients with oligoarticular or polyarticular subset

Methods We enrolled in a prospective, not-randomized, open-label study 349 PsA patients with peripheral disease, 234 with polyarticular and 115 with oligoarticular subset, beginning a treatment with adalimumab, etanercept, or infliximab. At baseline, 6 months, and 12 months, disease activity indices, (DAS28, Disease Activity Score on 28 joints, SDAI, simplified disease activity index, sum of TJC tender joint count, SJC swollen joint count, CRP C-reactive protein, and PzGA Patient Global Assessment), and disability HAQ (Health Assessment Questionnaire) were calculated. The rates of disease remission were compared among the three TNF-ablockers at 6 and 12 months. Baseline predictors of disease remission and functional improvement (reduction of HAQ ≥0.5) were analyzed by multivariate regression models

Results After 12 months the percentage of patients on clinical remission (SDAI ≤3.3) was significantly higher in infliximab or etanercept than adalimumab group (p<0.05), both in oligoarticular and polyarticular subset. Infliximab induced the widest decrease of TJC and the best “good” EULAR response in polyarthritis and oligoarthritis patients, respectively. Baseline predictors of disease remission were low DAS28, low HAQ, sex male, and glucocorticoids therapy in polyarthritis. The best predictor of functional improvement (ΔHAQ ≥0.5) was high HAQ in both subsets.

Conclusions Our study provides evidence that anti-TNFa drugs may differently perform in PsA and that separate analysis of the clinical subsets of the disease may improve our knowledge of the management of PsA

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.